Karyopharm Therapeutics had hoped to find a market for Xpovio (selinexor) in endometrial cancer based on subgroup findings from its SIENDO trial, but after conferring with the US Food and Drug Administration the firm will instead run a new clinical trial as it explores potential regulatory pathways for the drug. That means Xpovio will likely remain restricted to its current hematological cancer indications for at least the next three years.
Xpovio’s Solid Tumor Debut Faces Likely Three-Year Delay
Karyopharm will conduct another trial of the drug in p53 wild-type endometrial cancer after the FDA said SIENDO data were insufficient for approval.
More from Anticancer
• By
Investing heavily in antibody-drug conjugates, AbbVie is pioneering a dual STEAP1xPSMA-targeting approach in prostate cancer, as other candidates advance.
• By
Strong sales growth for the German group’s SGLT2 inhibitor in 2024
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
Merck expects Keytruda to come under Medicare price controls in 2028, but an analyst said the subcutaneous version could shield revenues for the franchise.
More from Therapy Areas
• By
The study’s failure in the overall MDD population was not a surprise, but solriamfetol’s efficacy in MDD with EDS provided a rationale for testing it in that subpopulation.
• By
After failing a Phase II monotherapy study in early Parkinson’s, Cerevance will focus on adjunctive therapy without abandoning the monotherapy concept.
• By
The firm has lofty ambitions for the aldosterone synthase inhibitor to treat hypertension and kidney disease.